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MicroRNAs (miRNAs) are short noncoding RNAs that
play crucial roles in tumorigenesis and tumor pro-
gression. Melanoma is the most aggressive skin can-
cer that is resistant or rapidly develops resistance to a
variety of chemotherapeutic agents. The role of
miRNAs in melanoma progression and drug resis-
tance has not been well studied. Herein, we demon-
strate that miR-200c is down-regulated in melanomas
(primary and metastatic) compared with melanocytic
nevi. Overexpression of miR-200c in melanoma cells
resulted in significantly decreased cell proliferation
and migratory capacity as well as drug resistance.
miR-200c overexpression resulted in significant
down-regulation of BMI-1, ABCG2, ABCG5, and MDR1
expression and in a concomitant increase in E-cad-
herin levels. Knockdown of BMI-1 showed similar
effects as miR-200c overexpression in melanoma
cells. In addition, miR-200c overexpression signifi-
cantly inhibited melanoma xenograft growth and me-
tastasis in vivo, and this correlated with diminished
expression of BMI-1 and reduced levels of E-cadherin
in these tumors. The effects of miR-200c on mela-
noma cell proliferation and migratory capacity and
on self-renewal were rescued by overexpression of
Bmi-1, and the reversal of these phenotypes corre-
lated with a reduction in E-cadherin expression and
increased levels of ABCG2, ABCG5, and MDR1. Taken
together, these findings demonstrate a key role for
miR-200c in melanoma progression and drug resis-
tance. These results suggest that miR-200c may repre-
sent a critical target for increasing melanoma sensi-
tivity to clinical therapies. (Am J Pathol 2012, 181:
1823–1835; http://dx.doi.org/10.1016/j.ajpath.2012.07.009)Melanoma is the most deadly skin cancer, and its inci-
dence is steadily rising. Survival in patients with distant
metastases (stage IV) is poor: 10-year survival ranges
from 6% to 15% in patients with stage IV disease.1,2
There is, therefore, a critical need to identify clinically
significant biochemical pathways central to the aggres-
sive behavior of this disease and, in the process, unveil
new opportunities for the design of rational therapeutic
interventions in high-risk patients. A key contributor to the
poor prognosis of advanced-stage melanoma is that
most melanomas are refractory to systemic therapies.3
The newly developed targeted antisignaling therapies,
such as vemurafenib and imatinib, showed great promise
in the treatment of melanomas with BRAF or CKIT muta-
tions, but these melanomas rapidly acquired resistance,
and the median duration of response was only 6 to 10
months.4–6 A variety of mechanisms have been pro-
posed to explain the observed resistance to systemic
therapeutic agents, including reduced intracellular accu-
mulation of drug and derangements in pathways control-
ling apoptosis, cell cycle checkpoints, and the repair of
damaged cellular targets.3,7 Indeed, in melanoma, mem-
bers of the ATP-binding cassette (ABC) transporters—a
superfamily of transmembrane proteins that transport
many varied substrates across biological membranes in
an ATP-dependent manner—exhibit high levels of ex-
pression and mediate chemoresistance in melanoma
cells.3,8 In particular, ABCG2 exhibits increased expres-
sion in melanoma cells with enhanced tumorigenic capa-
bilities, including the capability for self-renewal and dif-
ferentiation.9
The Polycomb group (PcG) of proteins comprises an
important class of transcriptional repressors that orches-
trate changes in chromatin structure to regulate gene
activity, and many of the PcG proteins demonstrate al-
tered expression in human cancers.10,11 BMI-1 is a PcG
protein that has been shown to be an important transcrip-
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encodes two separate gene products—p16ink4a and
p19Arf—from two distinct reading frames. p16ink4a inhibits
CDK activity and, thereby, blocks entry into the cell cycle
by preventing phosphorylation (and consequent inactiva-
tion) of the retinoblastoma protein (Rb) by cyclin
D–CDK4/6 complexes. p19ARF arrests cell cycle progres-
sion and promotes apoptosis by promoting the stability of
p53.14 BMI-1 also plays a critical role in the maintenance
of stem cells.15 Consistent with these observations sug-
gesting an important oncogenic role for BMI-1, BMI-1
overexpression has been demonstrated in numerous hu-
man cancers,10,11 including melanoma.16
MicroRNAs (miRNAs) are noncoding RNAs of approx-
imately 20 to 22 nucleotides that function in posttran-
scriptional gene regulatory pathways. Alterations in
miRNA expression have been described in many differ-
ent human tumors, and numerous studies have demon-
strated that miRNAs function as key pathogenic compo-
nents, impacting cancer cell growth, survival, and the
capacity to metastasize.17–22 In particular, the miR-200
family (including miR-200a, miR-200b, miR-200c, and
miR-141) has been shown to repress Zinc finger E-box
binding homeobox proteins 1 and 2 (ZEB1/ZEB2) in a
variety of different cellular contexts, culminating in in-
creased E-cadherin expression; in contrast, loss of miR-
200, which occurs in many different human cancers, in-
cluding breast cancer,23 ovarian cancer,24 prostate
cancer,25 and endometrial carcinoma,26 results in in-
creased ZEB1/ZEB2 and repression of E-cadherin and
represents the hallmark of the so-called epithelial to mes-
enchymal transition pathway.27–29 This latter change is
coincident with more aggressive biological behavior in
cancer (increased migration and invasion).23,28,30,31
Herein, we demonstrate a delicate interaction among
miR-200c, BMI-1, and drug resistance genes represent-
ing a pivotal cellular axis impacting not only the capacity
of melanoma cells to proliferate and metastasize but also
their sensitivity to systemic therapeutic agents.
Materials and Methods
Reagents and Cell Culture
We compared the miRNA expression profiles of benign
nevi (n  10), primary melanomas (n  10), and meta-
static melanomas (n  10) by microarray as previously
described.32 Total RNA extraction was performed as pre-
viously described.33 Tissue samples were obtained from
archives in the Department of Pathology and Laboratory
Medicine, Hospital of the University of Pennsylvania (Phil-
adelphia). The protocol was approved by the University
of Pennsylvania Institutional Review Board. Human mel-
anoma cell lines (WM35, WM793, WM115A, WM3523A,
and 1205Lu) were gifts from Meenhard Herlyn at The
Wistar Institute, Philadelphia. Human melanoma cell lines
were maintained in 2% MCDB medium as described.34
Human 293T cell line was a gift from Frank Lee at the
University of Pennsylvania, and they were maintained in
high-glucose Dulbecco’s modified Eagle’s medium with10% fetal bovine serum and penicillin/streptomycin (100
U/mL and 100 mg/mL). Nude mice were purchased from
The Jackson Laboratory (Bar Harbor, ME). All the animal
protocols were approved by the Institutional Animal Care
and Use Committee at the University of Pennsylvania.
The following antibodies were used: anti-goat BMI-1
(c1510; Santa Cruz Biotechnology, Santa Cruz, CA;
1:200 dilution), monoclonal mouse anti-human E-cad-
herin antibody (Dako, Carpinteria, CA; 1:500 dilution), rat
monoclonal anti-human ABCG2 antibody (sc- sc-69989;
Santa Cruz Biotechnology; 1:200 dilution), rabbit poly-
clonal to ABCG5 antibody (ab69713; Abcam Inc, Cam-
bridge, MA; 1:500 dilution), rabbit polyclonal MDR1 anti-
body (LS-B1448; LifeSpan Biosciences Inc., Seattle, WA;
1:200 dilution), and mouse anti--actin monoclonal anti-
body (010M4816; Sigma-Aldrich, St. Louis, MO; 1:2500
dilution).
pEIZ–HIV–ZsGreen–miR-200c, pEIZ-HIV-ZsGreen-vec-
tor, c-cherry vector, and c-cherry–Bmi-1 were gifts from M.
Clarke at Stanford University (Stanford, CA)23; the WST-1
cell proliferation kit was purchased from Roche Diagnos-
tics GmbH (Mannheim, Germany) (11974100) and was
performed according to the manufacturer’s instructions;
and FuGENE6 transfection reagent was purchased from
Roche Diagnostics GmbH (12132000) and was used ac-
cording to the manufacturer’s instructions.
RNA Isolation and Quantitative RT-PCR
Total RNA was isolated using the RNeasy kit (Qiagen
Inc., Valencia, CA), followed by cDNA synthesis using the
SuperScript first-strand synthesis system (Invitrogen,
Carlsbad, CA). Quantitative PCR was performed using iQ
SYBR green supermix (Bio-Rad Laboratories, Hercules,
CA) with the specific primers listed below. cDNA corre-
sponding to 1 g of RNA was added to the iQ SYBER
green supermix and was analyzed using an iCycler ther-
mal cycler (Bio-Rad Laboratories) according to the man-
ufacturer’s instructions. The thermal profiles were 95°C
for 30 seconds and 56°C for 30 seconds. Melting curve
analysis was performed for each PCR to confirm the
specificity of amplification. At the end of each phase,
fluorescence was measured and quantified. Hsa–miR-
200c TaqMan miRNA assay and GAPDH were pur-
chased from Applied Biosystems (Foster City, CA). BMI-1
RT-PCR was performed as described.35 Real-time PCR
primers were as follows: E-cadherin forward primer, 5=-
TTCCCTGCGTATACCCTGGT-3=; E-cadherin reverse primer,
5=-GCCATCTCTTGCTCGAAGTCC-3=; ABCG2 forward
primer, 5=-CAATGGGATCATGAAACCTG-3=; ABCG2 re-
verse primer, 5=-GAGGCTGATGAATGGAGAA-3=; ABCG5
forward primer, 5=-TGGGACATCACATCTTGCCG-3=; ABCG5
reverse primer, 5=-CCGTTCACATACACCTCCCC-3=; MDR1
forward primer, 5=-AGGAAGCCAATGCCTATGACTTTA-3=;
MDR1 reverse primer, 5=-CAACTGGGCCCCTCTCTCTC-
3=; -actin forward primer, 5=-TGACTGACTACCTCAT-
GAAGATCC-3=; and -actin reverse primer, 5=-GC-
CATCTCTTGCTCGAAGTCC-3=. -Actin was used as
an internal control, and iCycler iQ software version
3.1.0.7050 (Bio-Rad Laboratories) was used for analyz-
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and MDR1.
Infection of pEIZ–HIV–ZsGreen–miR-200C and
c-Cherry–Bmi-1
pEIZ-HIV-ZsGreen-vector control, pEIZ-HIV-ZsGreen
containing miR-200c, c-cherry–vector control, and
c-cherry–vector containing Bmi-1 (gifts from M. Clarke),
sh control, and sh-Bmi-136 were transfected into 293T
cells with packing vector (pCMV-dR8.2-dupr and pCMV-
VSV), and viral supernatants were collected 72 hours
after transfection to infect human melanoma cells
(WM115A, WM35, WM793, WM115A, and 1205Lu). After
a 48-hour infection period, miR-200c–infected green flu-
orescent protein–positive (green) cells were sorted by
fluorescence-assisted cell sorting (FACS). For the rescue
assay, we co-infected the BMI-1 virus into the miR-200c–
overexpressing cells. miR-200c and BMI-1 expression
were confirmed in the sorted cells by PCR or Western blot
analysis.
Cell Proliferation Assay
A total of 5  104 cells per well were seeded into a
24-well plate. After 48 hours, the absorbance at 450 nm
(A450) was detected using an iQuant universal micro-
plate spectrophotometer (BioTek Instruments Inc., Win-
ooski, VT) as previously described.37
Wound-Healing Assay
WM115A control cells, WM115A cells overexpressing
miR-200c, WM35 control cells, WM35 cells overexpress-
ing Bmi-1, WM115A control cells, WM115A cells with
Bmi-1 knock down, and WM115A cells overexpressing
BMI-1 and miR-200c were grown to confluence and were
wounded by dragging a 1-mL pipette tip across the
monolayer. The cells were washed to remove cellular
debris and then were allowed to migrate for 24 or 36
hours. Images were taken 0, 24, or 36 hours after wound-
ing using a DMI6000 inverted microscope (Leica Micro-
systems GmbH, Wetzlar, Germany). Three replicates
each of two independent experiments were performed.37
Western Blot Analysis
Western blot analysis was performed as previously de-
scribed.37
Cell Cycle Analysis
Cell viability was detected by trypan blue exclusion as-
say. A total of 1  106 miR-200c overexpression and
control-WM115A cells were harvested, rinsed twice with
Ca2, Mg2-free cold PBS, and fixed with 70% ethanol
overnight at 4°C. Fixed cells were then washed twice with
Ca2, Mg2-free cold PBS and stained with 20 g/mL
propidium iodide. The analysis was performed on a FAC-
SCalibur flow cytometer (BD Biosciences, San Jose, CA)using CellQuest Pro software (BD Biosciences). Cell cy-
cle analysis was performed using ModFit software ver-
sion 3.2.1 (Verity Software House, Topsham, ME).
Soft Agar Colony Formation Assay
A total of 1  104 WM115A control cells, WM115A cells
overexpressing miR-200c, or WM115A cells overex-
pressing BMI-1 andmiR-200C were resuspended in 3 mL
of 1.8% (w/v) Bacto Agar solution containing MCDB with
20% fetal bovine serum. The mixtures were overlaid onto
a 3.3% (w/v) Bacto Agar solution in 6-well dishes. After 24
hours, 0.5 mL of MCDB supplemented with 2.0% fetal
bovine serum was added. Colonies were counted under
a microscope after 15 days. Colony-forming efficiency
was calculated by the number of colonies  100/the
number of cells plated.37
Limiting Dilution Assay
WM115A control cells, WM115A cells overexpressing
miR-200c, or WM115A cells overexpressing BMI-1 and
miR-200c were trypsinized, washed, and resuspended at
a concentration of 100 cells/mL. A total of 10 L of this
cell suspension was dispensed into individual wells of
96-well plates containing 90 L of MCDB media supple-
mented with 2% fetal bovine serum. All the plates were
examined to confirm that each well contained only a
single cell. The cells were incubated for another 7 days,
with changes in media every other day. Colonies were
counted in single-cell seeded wells.
Xenograft Tumor Model
Four- to five-week-old male athymic nu/nu mice were
used in this study. Control or pEZX-miR-200c–infected
WM115A cells (2  106 cells per animal) were injected
subcutaneously into nude mice (eight mice per group).
After 35 days, the animals were sacrificed, and necropsy
was performed on each animal for further analysis of the
primary tumor along with possible metastases.
Statistical Analysis
A t-test or one-way analysis of variance was used to
analyze gene expression and cell viability. Statistical sig-
nificance was set at two-sided P  0.05.
Results
miR-200 Expression Is Decreased in Melanoma
Tissues and Cell Lines
We previously demonstrated that formalin-fixed, paraffin-
embedded tissue is a suitable resource for miRNA ex-
pression profiling.33,38 We, therefore, used formalin-fixed,
paraffin-embedded tissues consisting of 10 nevi, 10 pri-
mary melanomas, and 10 metastatic melanomas using a
microarray platform to examine miRNA expression. We
demonstrate a striking reduction in miR-200c expression
etastatic
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reduced expression in metastatic compared with primary
melanomas (Figure 1, A and B). We then examined miR-
200c expression in five melanoma cell lines isolated from
various stages of melanoma progression. 1205Lu,
WM3523A, and WM115A were derived from metastatic
melanomas. These cells consistently expressed lower
levels of miR-200c by quantitative RT-PCR compared
with WM35 (derived from radial growth phase primary
melanoma) and WM793 (derived from vertical growth
phase primary melanoma) (Figure 1C). Bmi-1 has been
found to be a target for miR-200c.23 Indeed, the expres-
sion of Bmi-1 inversely correlated with miR-200c expres-
sion in tissue samples (Figure 1D) and cell lines (Figure
1E) at mRNA and protein expression levels. Together,
these results demonstrate a progressive diminution of
miR-200c expression in melanoma compared with nevi
and suggest a further reduction in expression during
melanoma progression, and Bmi-1 expression correlates
inversely with miR-200c expression.
miR-200c Inhibits Melanoma Cell Proliferation
To characterize the function of miR-200c in melanoma
cells, we examined the effects of miR-200c overexpres-
sion in human melanoma cell lines. We infected
WM115A, 1205Lu, WM793, WM3523A, and WM35 cells
with lentivirus carrying miR-200c with a green fluorescent
protein tag. Green fluorescent protein–expressing cells
Figure 1. miR-200c mRNA expression levels decrease in metastatic melano
(P  1.09  104). Each dot represents relative expression level from one
standard deviation. B: Quantitative RT-PCR analysis of miR-200c expression
3 replicate experiments). Data are given as mean  SD. *P  0.05 compar
WM793, WM115A, WM3523A, and 1205Lu cells (n 3 replicate experiments)
of BMI-1 expression in tissue from 10 nevi, 10 primary melanomas, and 10 m
and Western blot analysis (bottom panel) of BMI-1 expression in WM35, Wwere sorted out by FACS 48 hours after infection (datanot shown). Cell proliferation was examined by the WST-1
proliferation assay. Enforced expression of miR-200c
caused a significant reduction in cell proliferation com-
pared with the control group (Figure 2A). To further char-
acterize the nature of this defect, we performed a cell
cycle progression study using FACS analysis in WM115A
cells infected with miR-200c. Overexpression of miR-
200c results in fewer cells in the S and G2-M phases
(mean  SD: 53.89%  8.19% in control cells compared
with 29.73%  2.37% in WM115A cells overexpressing
miR-200c) with a concomitant increase in G0-G1 (mean
SD: 46.10%  4.98% in control cells compared with
70.21%  11.07% in WM115A cells overexpressing miR-
200c; Figure 2B). Together with the results of the WST-1
cell proliferation assay, this finding is consistent with a
model in which enforced expression of miR-200c com-
promises progression through G0-G1.
To assess the tumorigenic effects of miR-200c in
WM115A cells, we performed soft agar colony formation
assays in cells overexpressing miR-200c. Compared with
control cells, enforced expression of miR200c resulted in
a significant reduction in the number of colonies formed
in soft agar (Figure 2C). Since enforced expression of
miR-200c impedes cell proliferation, we asked whether
enforced expression of miR-200c would affect cell sur-
vival in the presence of therapeutic agents. WM115A
melanoma cells were incubated with varying concentra-
tions of cisplatin (a DNA damaging agent), PLX4720 (a
specific inhibitor of B-RAFV600E), and U0126 (a selective
es and cell lines. A: Relative expression of miR-200c by microarray analysis
specimen and each bar represents mean of relative expression level with
e from 10 nevi, 10 primary melanomas, and 10 metastatic melanomas (n 
control. C: Quantitative RT-PCR analysis of miR-200c expression in WM35,
e given as mean SD. *P 0.05 compared with control. D: RT-PCR analysis
melanomas (n  3 replicate experiments). E: RT-PCR analysis (top panel)




. Data arinhibitor of MEK1/2 kinase) for 24 hours. miR-200c over-
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AJP November 2012, Vol. 181, No. 5Figure 2. miR-200c overexpression inhibits melanoma cell growth and cell mobility. A: Effect of miR-200c on WM115A melanoma cell proliferation by
WST-1 cell proliferation assay. The relative density of WM115A, 1205Lu, WM3523A, WM793, and WM35 melanoma cells infected with control vector and
pHIV–miR-200c were detected at 450 nm (A450) of absorbance (n  3 replicate experiments). Data are given as mean  SD. *P  0.05 compared with
control. B: Effect of miR-200c on WM115A melanoma cell cycle progression. Control and miR-200c–WM115A cells in the G0-G1, G2-M, and S phases
underwent FACS analysis (representative flowchart from 3 replicate experiments). C: Effect of miR-200c on WM115A melanoma cell soft agar colony
formation assay. Control and miR-200c–WM115A were cultured in soft agar. The clones were counted using a microscope at 100 magnification. The values
(colony number) are expressed as mean  SD from three separate measurements. *P  0.05 compared with control. D: Effect of miR-200c on WM115A
melanoma cell migration. Wound healing of control and miR-200c WM115A cells 0 and 24 hours after scratch formation. Shown are representative images
from 3 experiments. E: Effect of miR-200c on WM115A melanoma cell self-renewal. A limiting dilution assay was performed, and single cells were followed
for 14 days using control and miR-200c. The number of colonies formed was counted and averaged in three replicate experiments. Data are given as mean 
SD. *P  0.05 compared with control. F: Effect of miR-200c on WM115A melanoma cell survival in different drug environments: cisplatin, PLX4720, and
U0126 (n  3 replicate experiments). *P  0.05 compared with control.
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vival in all therapeutic agents tested (Figure 2F).
Since miR-200 family members are known to be key
regulators of E-cadherin expression in the epithelial to
mesenchymal transition, we also examined the impact of
enforced expression of miR-200c on WM115A cell migra-
tion. In wound-healing assays, enforced expression of
miR200c in WM115A cells resulted in a significant reduc-
tion in their capacity to close an artificial wound com-
pared with control cells (Figure 2D). Finally, we assessed
the effects of enforced miR-200c expression on the
self-renewal capacity of WM115A cells by limiting di-
lution assay and demonstrated a significant reduction
in colony-forming units (Figure 2E).
miR-200c Inhibits BMI-1 and Increases
E-Cadherin Expression Levels in WM115A Cells
In breast cancer cells, miR-200c directly binds to BMI-1 and
regulates its expression.23 Therefore, we asked whether
enforced expression of miR-200c would also affect BMI-1
expression in melanoma cells. Enforced expression of miR-
200c in WM115A cells resulted in a marked reduction of
BMI-1 mRNA (Figure 3A) and protein (Figure 3B) expres-
sion compared with controls. Furthermore, enforced ex-
pression of miR-200c in WM115A cells resulted in signifi-
cantly increased expression of E-cadherin (Figure 3, C and
E). Finally, since enforced expression of miR-200c results in
decreased survival of cells grown in the presence of cispla-
tin, PLX4720, and U0126, we studied whether enforced
expression of miR-200c impacted ABC transporter expres-
sion, which is well-known to be involved in drug resis-tance.8,9,39 We demonstrated that enforced expression of
miR-200c significantly reduces the expression of ABC
transporters ABCG2, ABCG5, and MDR1 (Figure 3, D and
E) compared with control cells.
Bmi-1 Knockdown Phenocopies miR-200c
Overexpression
To further assess the relationship between Bmi-1 and
miR-200c in melanoma cells, we asked whether deple-
tion of Bmi-1 would have similar effects as miR-200c
overexpression. We knocked down Bmi-1 expression
in WM115A cells as previously described.36 Decreased
expression of Bmi-1 mRNA and protein was confirmed by
RT-PCR and Western blot analysis, respectively (Figure
4A). Bmi-1 knockdown in WM115A cells resulted in de-
creased cell proliferation (Figure 4B), increased sensitiv-
ity to varying concentrations of cisplatin and PLX4720
(Figure 4B), and diminished cell migration (Figure 4C).
These changes correlated with down-regulation of
ABCG2, ABCG5, and MDR1 (Figure 4D), findings similar
to those seen after miR-200c overexpression. Further-
more, Bmi-1 overexpression in WM35, a radial growth
phase melanoma cell line, promoted cell proliferation and
migration (Figure 4E).
Bmi-1 Rescues the Effects of miR-200c on
WM115A Cells
To confirm that the effects of miR-200c are mediated
through Bmi-1 in melanoma, we introduced Bmi-1 (with a
cherry-red tag) into miR-200c–overexpressing WM115A
Figure 3. miR-200c overexpression correlates
with decreased BMI-1, ABCG2, ABCG5, and MDR1
and increased E-cadherin expression levels in
WM115A cells. A: RT-PCR analysis of BMI-1 ex-
pression in control and miR-200c–WM115A (n  3
replicate experiments). B: Expression of BMI-1 by
Western blot analysis. Cell lysates from control and
miR-200c–WM115A were used for Western blot
analyses with anti-Bmi1 antibody, -actin was used
as loading controls (n  3 replicate experiments).
C: Quantitative RT-PCR analysis of E-cadherin ex-
pression in control and miR-200c–WM115A (n  3
replicate experiments). Data are given as mean 
SD. *P  0.05 compared with control. D: Quanti-
tative RT-PCR analysis of ABCG2, ABCG5, and
MDR1 expression in control and miR-200c–
WM115A (n  3 replicate experiments). Data are
given as mean  SD. *P  0.05 compared with
control. E Expression of E-cadherin, ABCG2,
ABCG5, and MDR1 by Western blot analysis in
control and miR-200c–WM115A (n  3 replicate
experiments).
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was confirmed by RT-PCR and Western blot analysis,
respectively (Figure 5A). Enforced expression of BMI-1
reversed the inhibitory effects of miR-200c on cell prolif-
eration, restoring WM115A cell proliferation to endoge-
nous levels (WST-1 assay; Figure 5B). BMI-1 also re-
versed the negative effects of miR-200c overexpression
on the capacity of WM115A cells to undergo self-renewal,
restoring their ability to form colonies in a limiting dilution
assay to wild-type levels (Figure 5, C and F). In addition,
BMI-1 restored the sensitivity of miR-200c–overexpress-
ing WM115A cells to varying concentrations of cisplatin,
PLX4720, and U0126 (Figure 5D), and this correlated
with a reversal of the miR-200c–induced down-regulation
of ABCG2, ABCG5, and MDR1 (Figure 5G). Finally, en-
forced expression of BMI-1 in miR-200c–overexpressing
WM115A cells restored their capacity to undergo cell
migration in a wound-healing assay (Figure 5E), and this
correlated with a reversal of the miR-200c–induced up-
regulation of E-cadherin mRNA and protein (Figure 5G).
miR-200c Inhibits Melanoma Growth and
Metastasis in Vivo
To assess the effect of miR-200c on tumor growth and
metastasis in vivo, we injected control or miR-200c–WM115A cells into the flanks of nude mice (eight mice
for each group). The mice were observed for 5 weeks,
and the resultant xenograft tumors were harvested. The
xenografts formed by miR-200c–WM115A cells were
significantly smaller than those formed by control cells
(Figure 6, A–C), and this correlated with increased
levels of miR-200c in these tumors. Necropsies were
performed, and organs were examined for the pres-
ence of metastases. We found a significantly higher
rate of metastasis in tumors derived from WM115A
control cells compared with tumors derived from
WM115A cells overexpressing miR-200c (40% com-
pared with 10%; Figure 6E).
Finally, we examined the expression of Bmi-1 and E-
cadherin in the primary xenograft tumors (formed by miR-
200c–WM115A and WM115A control cells) and their me-
tastases (derived from control cells). Bmi-1 mRNA and
protein (Figure 7A) were reduced in the miR-200c–
WM115A tumors compared with the WM115A control tu-
mors and their respective metastases. In addition, E-
cadherin was reduced in WM115A control tumors and
their respective metastases compared with miR-200c–
WM115A tumors (Figure 7, B, C, and E). Finally, there
was a progressive, statistically significant decrease in the
levels of ABCG2, ABCG5, and MDR1 mRNA and protein
Figure 4. Knockdown of Bmi-1 phenocopies
miR-200c overexpression in WM115A melanoma
cells. A: RT-PCR analysis of BMI-1 expression in
control and sh-Bmi-1–WM115A (n  3 replicate
experiments) (top panel) and expression of
BMI-1 by Western blot analysis (bottom panel).
Cell lysates from control and sh-Bmi-1–WM115A
were used for Western blot analyses with anti-
Bmi1 antibody. -Actin was used as loading con-
trols (n  3 replicate experiments). B: Left panel:
Effect of sh-Bmi-1 on WM115A melanoma cell
proliferation by WST-1 cell proliferation assay.
The relative density of WM115A cells infected with
control vector and sh-Bmi-1 were detected at 450
nm (A450) of absorbance (n  3 replicate exper-
iments). *P  0.05 compared with control. Right
panel: Effect of Bmi-1 knock down on WM115A
melanoma cell survival in different drug environ-
ments (cisplatin and PLX4720) (n  3 replicate
experiments). Data are given as mean  SD. *P 
0.05 compared with control. C: Effect of sh-Bmi-1
on WM115A melanoma cell migration. Wound
healing of control and sh-Bmi-1 WM115A cells 0
and 24 hours after scratch formation. Shown are
representative images from three experiments. D:
Quantitative RT-PCR (left panel) and Western
blot (right panel) analyses of E-cadherin,
ABCG2, ABCG5, and MDR1 expression in control
and sh-Bmi-1–WM115A (n  3 replicate experi-
ments). Data are given as mean  SD. *P  0.05
compared with control. E: Left panel: Expression
of BMI-1 by Western blot analysis. Cell lysates
from control and Bmi-1–WM35 were used for
Western blot analyses (n  3 replicate experi-
ments). Middle panel: Wst-1 assay analysis of
control and Bmi-1–WM35 cell proliferation at 450
nm. Data are given as mean  SD. *P  0.05
compared with control. Right panel: Wound-
healing assay showed the increased cell motility
ability in Bmi-1–overexpressed (OE) WM35 cells
compare with control (n  3 replicate experi-
ments).expression in the xenografts formed by miR-200–
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AJP November 2012, Vol. 181, No. 5Figure 5. BMI-1 rescues the effects of miR-200c on WM115A melanoma cells. WM115A cells were co-transfected with c-cherry control and miR-200c or with
c-cherry–BMI-1 and miR-200c as indicated (n  3 replicate experiments). A: Left panel: RT-PCR analysis confirms increased BMI-1 mRNA expression in c-cherry
BMI-1–miR-200c–WM115A cells compared with c-cherry control–miR-200c–WM115A (-actin loading control, n  3 replicate experiments). Right panel:Western blot
analysis confirms increased BMI-1 protein expression in c-cherry BMI-1–miR-200c–WM115A cells compared with c-cherry control–miR-200c–WM115A (-actin loading
control, n  3 replicate experiments). B: BMI-1 overexpression reverses the negative impact of miR-200c on cell proliferation. WST cell proliferation assay: c-cherry
control–miR-200c–WM115A and c-cherry BMI-1–miR-200c–WM115A cells were detected at 450 nm (A450) of absorbance (n  3 replicate experiments). *P  0.05
compared with control. C: BMI-1 overexpression reverses the negative impact of miR-200c on the ability of WM115A cells to form colonies in soft agar. C-cherry control–
miR-200c––WM115A and c-cherry BMI-1–miR-200c–WM115A were cultured in soft agar. Colonies were counted using a microscope at 100 magnification. The values
(colony number) are expressed as mean SD from three separate measurements. *P 0.05 compared with control cells.D: BMI-1 expression reverses chemosensitivity
phenotype of enforced miR-200c expression in WM115A cells. Cell survival in cisplatin, PLX4720, and U0126 in c-cherry control–miR-200c–WM115A and c-cherry
BMI-1–miR-200c–WM115A cells (n  3 replicate experiments). *P  0.05 compared with control. E: BMI-1 overexpression reverses the negative impact of miR-200c on
cell migration. Wound healing of c-cherry control–miR-200c–WM115A and c-cherry BMI-1–miR-200c–WM115A cells 0 and 36 hours after scratch formation. Shown are
representative images from three experiments. F: BMI-1 overexpression reverses the negative impact of miR-200c on the capacity of WM115A cells to undergo
self-renewal. A limiting dilution assay was performed, and single cells were followed for 14 days using c-cherry control– miR-200c–WM115A and c-cherry Bmi-1–miR-
200c–WM115A. The number of colonies formed was counted and averaged in three replicate experiments. *P  0.05 compared with control. G: BMI-1 overexpression
reverses the impact of miR-200c overexpression on E-cadherin, ABCG2, ABCG5, and MDR1. Left panel: Quantitative RT-PCR analysis demonstrate relative levels of
E-cadherin, ABCG2, ABCB5, and MDR1 in c-cherry control–miR-200c–WM115A, and c-cherry BMI-1–miR-200c–WM115A cells (n  3 replicate experiments). *P  0.05
compared with control. Right panel:Expression of E-cadherin, ABCG2, ABCG5, andMDR1 byWestern blot analysis in c-cherry control–miR-200c–WM115A and c-cherry
BMI-1–miR-200c–WM115A cells (n  3 replicate experiments). Data are given as mean  SD.
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metastases, respectively (Figure 7, D and E).
Discussion
There is a critical need to improve our understanding of
the molecular pathogenesis of melanoma. In a previous
study, we described a distinct pattern of miRNA expres-
sion in nevi compared with melanomas.32 Herein, we
describe a progressive diminution of expression of miR-
200c in primary and metastatic melanomas compared
with melanocytic nevi and in melanoma cell lines derived
frommelanoma metastases compared with those derived
from radial or vertical growth phase–only primary mela-
noma. In melanoma cells, miR-200c impacts pathways
governing cell proliferation, self-renewal, drug sensitivity,
and cell migration. Together, the present findings provide
evidence of a pivotal role in melanoma progression and
resistance to chemotherapeutic agents between the in-
terconnected network of miR-200c, BMI-1, E-cadherin,
and ABC transporters (ABCG2, ABCG5, and MDR1).
BMI-1 expression is up-regulated in numerous hu-
man cancers,10,11,40–55 including melanoma.16 In-
creased BMI-1 seems to correlate with a more aggres-
sive phenotype. Primary melanomas with metastases
demonstrated increased BMI-1 expression compared
Figure 6. miR-200c inhibits melanoma growth and metastasis in vivo. A:
Xenografts are shown (in each panel, the left side shows miR-200c–WM115A
and the right side shows control). B: Histopathologic examination of
WM115A control cell or miR-200c–WM115A cell tumors. C: Average tumor
weights are shown (generated by WM115A control cells and miR-200c–
WM115A cells, respectively; n  8). *P  0.05 compared with control. D:
Quantitative RT-PCR analysis of miR-200c expression in xenograft from
WM115A control tumors and miR-200c–WM115A tumors (n  3 replicate
experiments).*P  0.05 compared with control. E: Frequency of metastases
from tumors generated by WM115A control cells and miR-200c–WM115A
cells, respectively.). *P  0.05 compared with control. Data are given as
mean  SD.with primary melanomas without metastases (83% com-pared with 52%).16 Similar findings have been described
in breast carcinoma, where there is a statistically signifi-
cant relationship between BMI-1 expression and the
presence of axillary lymph node metastases.46 Increased
BMI-1 expression also correlated with either a worse out-
come or a more aggressive cancer phenotype in naso-
pharyngeal carcinoma,40 colonic adenocarcinoma,41
gastric carcinoma,42 and hepatocellular carcinoma.44 Al-
though the mechanism by which cancer cells acquire
BMI-1 up-regulation is unclear, studies in different cancer
cell types demonstrate a central role for miRNAs in this
process. In ovarian carcinoma cells, BMI-1 is targeted by
miR-15a and miR1656; in endometrial carcinoma cells,
miR-194 represses a BMI-1–mediated epithelial to mes-
enchymal transition57; and in breast carcinoma and glio-
blastoma, miR-128 represses BMI-158,59 Finally, miR-
200c targets BMI-1 in breast and pancreatic cancer, and
this functional relationship provided an important mech-
anistic association between miRNAs, epithelial to mesen-
chymal transition, and a stem cell–like phenotype.23,60 In
breast cancer stem cells, miR-200c expression was de-
creased compared with nontumorigenic breast cancer
cells; enforced expression of miR-200c not only re-
pressed BMI-1 expression but also compromised the
ability of breast cancer stem cells and normal mammary
stem cells to form tumors and normal mammary ducts in
vivo, respectively.23 Similarly, in pancreatic cancer, miR-
200c targets ZEB1 and BMI-1, both of which are required
to preserve stem cell–like properties (self-renewal, char-
acteristic marker expression, drug resistance, and tumor-
igenicity) in pancreatic cancer cells.60 Together with the
finding of an inverse relationship between ZEB1 expres-
sion in pancreatic carcinoma tissue samples and long-
term survival in those patients, these findings established
an important relationship between miR-200c, ZEB1/E-
cadherin (epithelial to mesenchymal transition), and
BMI-1. Namely, miR-200c directly represses ZEB1 and
BMI-1; in turn, diminished expression of miR-200c corre-
lates with acquisition of a stem cell–like phenotype during
the course of tumor progression.60
The present findings in clinical specimens and cell
lines provide additional support for such a model in mel-
anoma progression. miR-200c exhibits progressively di-
minished expression from benign melanocytic nevi to
primary melanomas in human tissue and in cell culture,
and the expression of Bmi-1 correlates inversely with
miR-200 expression. Similar to a recent report describing
diminished expression of miR-200c in melanoma and a
reduced capacity for colony formation when miR-200c is
overexpressed,61 we demonstrate that enforced expres-
sion of miR-200c in melanoma cells impaired cell prolif-
eration and self-renewal, enhanced drug sensitivity, and
compromised cell migration. These phenotypic altera-
tions were accompanied by a decrease in the expression
of BMI-1, ABCG2, ABCB5, and MDR1 and a concomitant
increase in E-cadherin expression. Enforced expression
of Bmi-1 in these same cells reversed the phenotypic
effects of miR-200c, whereas knockdown ofBmi-1 seems to
phenocopy miR-200c overexpression. The expression of
miR-200 family members in melanoma and their effect on
cell migration in melanoma cells is somewhat controversial.
stern bl
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200c seem to be overexpressed in melanoma cell lines
compared with normal human melanocytes, whereas the
present results and others characterizing miRNA expres-
sion patterns in tissue samples of melanomas and nevi63
demonstrated a progressive diminution in their expres-
sion. In addition, Elson-Schwab et al62 found that over-
expression of miR-200c and miR-200a primarily affects
cell morphology, and miR-200c seems to promote cell
migration in certain melanoma cell lines using a three-
dimensional collagen I matrix. The discrepancy between
these findings is, in part, attributable to the differences in
cell lines and different assays used to define the role of
miR-200c in melanoma cells.62 Nevertheless, we showed
that melanoma cells overexpressing miR-200c devel-
Figure 7. miR-200c inhibits melanoma growth and metastasis through up-re
by quantitative RT-PCR (top panel) and of protein by Western blot analysis
and miR-200c–WM115A cells (-actin used as control). B: Immunohistochem
and miR-200c–WM115A cells (bottom panel). C: RT-PCR analysis of E
miR-200c–WM115A cells (n  3 replicate experiments). *P  0.05 compared
and MDR1 in xenografts generated by WM115A metastasis, WM115A contro
with control. E: Expression of E-cadherin, ABCG2, ABCG5, and MDR1 by We
cells (n  3 replicate experiments). Data are given as mean  SD.oped significantly smaller tumors with a reduced propen-sity for metastasis compared with controls, and the more
aggressive control tumors and their metastases exhibited
diminished expression of E-cadherin and increased ex-
pression of Bmi-1. These findings demonstrate that per-
turbations in the miR200c/Bmi-1/Zeb1/E-cadherin axis
correlate with a more aggressive melanoma phenotype.
We also demonstrate a functional relationship among
miR-200c, Bmi-1, and the expression of ABC transporters
(ABCG2, ABCG5, and MDR1), and this relationship af-
fects sensitivity to various chemotherapeutic agents. The
role of ABC transporters in mediating chemoresistance
during the course of melanoma progression has been
proposed to arise by exploiting pathways and molecules
that melanocytes normally express during melanogene-
sis.3,8 In benign pigment-synthesizing melanocytes, ABC
of E-cadherin and down-regulation of Bmi-1. A: Expression of BMI-1 mRNA
panel) in xenografts generated by WM115A metastasis, WM115A control,
ression of E-cadherin in xenografts from WM115A control cells (top panel)
n mRNA expression in xenograft generated by metastasis, control, and
ntrol. D: Quantitative RT-PCR analysis of relative levels of ABCG2, ABCG5,
iR-200c–WM115A cells (n  3 replicate experiments). *P  0.05 compared
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ious subcellular organelles, enabling these intermediates
to be safely exported from the cell. During the course of
melanoma progression, it has been hypothesized that
melanoma cells hijack these intrinsic pathways of mela-
nosome biosynthesis to impart a drug resistance pheno-
type.3,8 Indeed, aberrant ABC transporter expression
and function in melanoma is well described: ABCG2 ex-
hibits increased expression in so-called melanoma-initi-
ating cells, which function as melanoma stemlike cells
capable of self-renewal and differentiation.9 Other ABC
transporters (ABCB5) are expressed at high levels in
melanoma64 and mediate chemoresistance.39 Similar to
ABCG2, ABCB5 also exhibits increased expression in
melanoma-initiating cells, conferring a stem cell–like phe-
notype on these cells.65
However, the mechanisms by which the expression
and activity of these endogenously used transporters are
hijacked to effect drug resistance in melanoma cells are
not well defined. The present results implicate alterations
in miRNA expression in this process. Namely, enforced
expression of miR-200c coincides with reduced expres-
sion of Bmi-1, ABCG2, ABCG5, and MDR1 and increased
sensitivity to various chemotherapeutic agents. Enforced
expression of Bmi-1 seems to reverse these effects, con-
sistent with a model in which BMI-1, itself a known direct
target of miR-200c in other cancers,23 directly or indi-
rectly activates ABC transporter expression. Thus, loss of
miR-200c in melanoma progression would result in in-
creased levels of BMI-1 and ABC transporters and a
resultant chemotherapeutic resistance phenotype. Con-
sistent with this model is the observation of coincidently
increased BMI-1 and ABC transporter expression in hep-
atocellular carcinomas66 and ameloblastic tumors.67 Fu-
ture studies are needed to define more completely the
precise mechanisms whereby miR-200c and BMI-1 lever-
age ABC transporter expression and activity to affect
chemoresistance in melanomas.
Herein, we defined additional pivotal components in
the molecular pathogenesis of melanoma and high-
lighted important new opportunities for the rational de-
sign of targeted therapies. Relying first on patient
specimens, we identified a progressive diminution of
miR-200c expression in primary and metastatic mela-
nomas compared with nevi. We demonstrate further that
miR-200c governs the expression of an important axis in
melanoma progression, including BMI-1, E-cadherin, and
ABC transporters, which conspire together to regulate
cell proliferation, cell motility, and resistance to chemo-
therapeutic agents. Together, these results support the
utility of miRNA expression profiling as a powerful tool for
interrogating clinical samples of melanomas as a window
to clinically and biologically important pathways central
to the aggressive behavior of this disease.
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